ConductScience.org, home

Paper11029005

Immune control of HIV-1 after early treatment of acute infection.

Rosenberg ES and 9 others. Nature, 2000. Cited by 783 papers, by iCite.

Cite this record

ConductScience Library. Immune control of HIV-1 after early treatment of acute infection. Papers, record 11029005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11029005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune control of HIV-1 after early treatment of acute infection.
PubMed
Journal
Nature
PubMed
Year
2000
PubMed
Publication types
Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
783
iCite
Relative citation ratio, by iCite
16.1
iCite
Revised in PubMed
2006-11-15
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rosenberg ESE S
2Altfeld MM
3Poon SHS H
4Phillips MNM N
5Wilkes BMB M
6Eldridge RLR L
7Robbins GKG K
8D'Aquila RTR T
9Goulder PJP J
10Walker BDB D

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
HIV InfectionsMajor topic
HIV-1Major topic
Acute Disease
Adult
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Drug Administration Schedule
Drug Therapy, Combination
Gene Products, gag
Humans
Male
Pilot Projects
RNA, Viral
T-Lymphocytes, Helper-Inducer
Viral Load
Viremia

Source PubMed

Download CSV of topics

Trials5

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00058734Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected PatientsBackgroundClinicalTrials.gov
NCT00125099Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV InfectionBackgroundClinicalTrials.gov
NCT00183261Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV InfectionBackgroundClinicalTrials.gov
NCT02042248A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004BackgroundClinicalTrials.gov
NCT02208167Phase I Study of HIV 1 Antigen Expanded Specific T Cell TherapyBackgroundClinicalTrials.gov

Download CSV of trials

Cited by296

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 783 citations.

PMIDTitleJournalYearIn PapersSource
42698968How past transient viremia shape natural killer cells' antibody-dependent functions in youth with perinatal HIV.iScience2026https://conductscience.org/library/papers/42698968PubMed
42492499Feasibility, Acceptability, and Test Performance of Point-of-Care Nucleic Acid Tests for HIV Testing and Viral Load Monitoring in the United States: Prospective Longitudinal Mixed-Methods Study.JMIR Res Protoc2026https://conductscience.org/library/papers/42492499PubMed
41282862CD8+ T cell recall cytotoxicity during chronic treated HIV-1 infection is associated with limited reservoir size and activity.medRxiv2025https://conductscience.org/library/papers/41282862PubMed
40953113Clonal heterogeneity and antigenic stimulation shape persistence of the latent reservoir of HIV.PLoS Comput Biol2025https://conductscience.org/library/papers/40953113PubMed
40408432
Transmitted/founder (T/F) HIV-1 derived from sexual contact exhibits greater transmission fitness in human cervical tissue than T/F HIV-1 from blood-to-blood contact: Unique glycan profiles on T/F envelopes associated with transmission phenotypes.
PLoS Pathog2025https://conductscience.org/library/papers/40408432PubMed
40105005Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children.Curr Opin HIV AIDS2025https://conductscience.org/library/papers/40105005PubMed
39976231Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection.Elife2025https://conductscience.org/library/papers/39976231PubMed
39504491Rapid viral suppression using integrase inhibitors during acute HIV-1 infection.J Antimicrob Chemother2025https://conductscience.org/library/papers/39504491PubMed
39466203Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection.J Exp Med2024https://conductscience.org/library/papers/39466203PubMed
38932264
Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection.
Viruses2024https://conductscience.org/library/papers/38932264PubMed
38808136Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral control.Front Med (Lausanne)2024https://conductscience.org/library/papers/38808136PubMed
38620211Current situation in the development of a preventive HIV vaccine.Enferm Infecc Microbiol Clin2005https://conductscience.org/library/papers/38620211PubMed
38032851Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency.PLoS Pathog2023https://conductscience.org/library/papers/38032851PubMed
37949070Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV.Cell Rep Med2023https://conductscience.org/library/papers/37949070PubMed
36851349Cohort-Specific Peptide Reagents Broaden Depth and Breadth Estimates of the CD8 T Cell Response to HIV-1 Gag Potential T Cell Epitopes.Vaccines (Basel)2023https://conductscience.org/library/papers/36851349PubMed
36541802Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control.J Virol2023https://conductscience.org/library/papers/36541802PubMed
36207834Significance of initiating antiretroviral therapy in the early stage of HIV infection.Zhejiang Da Xue Xue Bao Yi Xue Ban2022https://conductscience.org/library/papers/36207834PubMed
35711433NK Cells, Monocytes and Macrophages in HIV-1 Control: Impact of Innate Immune Responses.Front Immunol2022https://conductscience.org/library/papers/35711433PubMed
34983387Application of quantile mixed-effects model in modeling CD4 count from HIV-infected patients in KwaZulu-Natal South Africa.BMC Infect Dis2022https://conductscience.org/library/papers/34983387PubMed
34961509Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.BMC Med Ethics2021https://conductscience.org/library/papers/34961509PubMed

See all 296 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11029005

GET https://conductscience.org/api/papers/v1/11029005/cited_by?page=2